This episode currently has no reviews.
Submit ReviewHas the fever broken for the high momentum stocks? Nvidia running out of steam this week, as some other high fliers also pull back. Is this just a bump in the road or the beginning of a summer slowdown? Plus Sarepta’s big surge. The biotech company getting expanded approval from the FDA for its muscular dystrophy drug. What the CEO says is next for the company.
This episode currently has no reviews.
Submit ReviewThis episode could use a review! Have anything to say about it? Share your thoughts using the button below.
Submit Review